269. 化膿性無菌性関節炎・壊疽性膿皮症・アクネ症候群
［臨床試験数：20，薬物数：26（DrugBank：10），標的遺伝子数：12，標的パスウェイ数：90］
Searched query = "Pyogenic arthritis", "Pyoderma gangrenosum", "Acne syndrome", "PAPA syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04274166 (ClinicalTrials.gov) | January 2021 | 12/2/2020 | Secukinumab for the Inflammatory Phase of Pyoderma Gangrenosum | The Efficacy and Safety of Secukinumab for the Inflammatory Phase of Pyoderma Gangrenosum | Pyoderma Gangrenosum | Drug: secukinumab 150 mg (2 injections per dose | Wake Forest University Health Sciences | Novartis | Not yet recruiting | 18 Years | 75 Years | All | 6 | Phase 2 | United States |
| 2 | NCT02733094 (ClinicalTrials.gov) | April 2016 | 28/3/2016 | Single-arm Study to Assess a Potential Effect of Anti-IL-17 (Secukinumab) in the Treatment of Pyoderma Gangrenosum | Single-arm Study to Assess a Potential Effect of Anti-IL-17 (Secukinumab) in the Treatment of Pyoderma Gangrenosum | Pyoderma Gangrenosum | Drug: Secukinumab | Technische Universität München | Novartis | Active, not recruiting | 18 Years | 75 Years | All | 8 | Phase 1;Phase 2 | Germany |
| 3 | EUCTR2015-000762-65-DE (EUCTR) | 09/07/2015 | 25/06/2015 | Single-arm study to assess a potential effect of anti-IL-17 (Secukinumab) in the treatment of pyoderma gangrenosu | Single-arm study to assess a potential effect of anti-IL-17 (Secukinumab) in the treatment of pyoderma gangrenosum | Pyoderma gangrenosum is an autoinflammatory disease, characterized by relapsing, painful ulcers of the skin. Treatment of PG is difficult. Patients suffer from long hospitalization, pain and reduced life quality. New therapeutic strategies are needed. Immunohistological staining show a high amount of IL-17 in PG. IL-17+ immune cells were located in proximity to cellular damage, indicating an involvement in the pathogenesis. Targeting IL-17 with neutralizing IL-17 antibodies seems promising. MedDRA version: 20.0;Level: PT;Classification code 10037635;Term: Pyoderma gangrenosum;System Organ Class: 10040785 - Skin and subcutaneous tissue disorders;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17] | Trade Name: Cosentyx® Product Name: Cosentyx Product Code: EU/1/14/980/002; EU/1/14/980/003 | Technische Universität München, School of Medicine, represented by Dean | NULL | Not Recruiting | Female: yes Male: yes | 7 | Phase 2;Phase 3 | Germany |